We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+7.47%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$12.3B
AUM Growth
+$1.06B
Cap. Flow
+$761M
Cap. Flow %
6.18%
Top 10 Hldgs %
58.32%
Holding
100
New
18
Increased
36
Reduced
17
Closed
19

Top Buys

Rank Stock Value
1
AET
Aetna Inc
AET
+$896M
2
COL
Rockwell Collins
COL
+$339M
3
MON
Monsanto Co
MON
+$161M
4
ELV icon
Elevance Health
ELV
+$131M
5
CHTR icon
Charter Communications
CHTR
+$92.5M

Top Sells

Rank Stock Value
1
BCR
CR Bard Inc.
BCR
+$508M
2
TWX
Time Warner Inc
TWX
+$393M
3
HDS
HD Supply Holdings, Inc.
HDS
+$196M
4
KITE
Kite Pharma, Inc.
KITE
+$175M
5
ALR
Alere Inc
ALR
+$138M

Sector Composition

Rank Sector Weight
1 Technology 22.48%
2 Healthcare 15.61%
3 Communication Services 13.96%
4 Financials 11.79%
5 Industrials 9.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
51
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$27.2M 0.22%
290,000
+53,784
+23% +$5.09M
NVCR icon
52
NovoCure
NVCR
$1.99B
$23.5M 0.19%
+1,165,000
New +$22.4M
NTLA icon
53
Intellia Therapeutics
NTLA
$1.8B
$21.9M 0.18%
+1,140,000
New +$26.3M
CRSP icon
54
CRISPR Therapeutics
CRSP
$5.75B
$20.2M 0.16%
+858,602
New +$16.3M
HRG
55
DELISTED
HRG Group, Inc.
HRG
$19.4M 0.16%
1,142,000
+157,000
+16% +$2.54M
SPB icon
56
Spectrum Brands
SPB
$2B
$19.1M 0.16%
170,000
+23,000
+16% +$2.51M
LUMN icon
57
PUT
Lumen
LUMN
$6.13B
$19.1M 0.16%
1,144,000
– –
PTGX icon
58
Protagonist Therapeutics
PTGX
$9.99B
$18.7M 0.15%
+900,000
New +$16M
EDIT icon
59
Editas Medicine
EDIT
$478M
$15.8M 0.13%
+515,000
New +$13M
CAVM
60
DELISTED
Cavium, Inc.
CAVM
$15.1M 0.12%
+180,000
New +$13.9M
IOVA icon
61
Iovance Biotherapeutics
IOVA
$3.76B
$14.9M 0.12%
1,866,900
+1,016,900
+120% +$8.16M
GBT
62
DELISTED
Global Blood Therapeutics, Inc.
GBT
$13.4M 0.11%
+340,000
New +$12.7M
HAIN icon
63
Hain Celestial
HAIN
$71.6M
$12.3M 0.1%
+290,000
New +$11.5M
AKBA icon
64
Akebia Therapeutics
AKBA
$251M
$12.3M 0.1%
825,000
+95,000
+13% +$1.58M
ASMB icon
65
Assembly Biosciences
ASMB
$700M
$11.3M 0.09%
+20,833
New +$9.43M
VYGR icon
66
Voyager Therapeutics
VYGR
$209M
$10.9M 0.09%
654,812
+487,147
+291% +$8.35M
CBAY
67
DELISTED
Cymabay Therapeutics
CBAY
$10.1M 0.08%
+1,100,000
New +$9.4M
BOLD
68
DELISTED
Audentes Therapeutics, Inc
BOLD
$9.99M 0.08%
+319,662
New +$8.78M
ZEAL
69
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$8.84M 0.07%
650,000
– –
WGL
70
DELISTED
Wgl Holdings
WGL
$8.58M 0.07%
100,000
-20,000
-17% -$1.71M
XPO icon
71
XPO
XPO
$23.2B
$8.24M 0.07%
+260,225
New +$6.65M
MRNS
72
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$7.3M 0.06%
223,750
-68,750
-24% -$1.85M
BG icon
73
Bunge Global
BG
$21.7B
$7.04M 0.06%
+105,000
New +$7.14M
NCNA
74
NuCana
NCNA
$6.33M
$4.04M 0.03%
80
– –
TROX icon
75
Tronox
TROX
$888M
$3.88M 0.03%
+189,375
New +$4.62M
1 2
3
4

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2017 Portfolio in Review

As of Q4 2017, Thomas Steyer held 100 positions worth $12.3B, up 9.4% from $11.3B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Thomas Steyer deployed $761M of net new capital in Q4 2017, opening 18 new positions and adding to 36 existing holdings. Its largest new stake was Aetna Inc: 5,215,000 shares worth $941M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Healthcare and Communication Services.

On the sell side, the largest reduction was Time Warner Inc, an estimated $393M trimmed.

  • Thomas Steyer's largest Q4 2017 buy was Aetna Inc: 5,215,000 shares worth $941M.
  • Thomas Steyer added most to Monsanto Co in Q4 2017, an estimated $161M increase.
  • Thomas Steyer's biggest Q4 2017 reduction was Time Warner Inc, cutting an estimated $393M.
  • Thomas Steyer fully exited CR Bard Inc. in Q4 2017, selling an estimated $508M.
  • Thomas Steyer's ten largest holdings make up 58% of its $12.3B portfolio in Q4 2017.
  • Thomas Steyer opened 18 new positions and closed 19 in Q4 2017.
  • Thomas Steyer's portfolio value rose 9.4% quarter-over-quarter to $12.3B.

Based on Farallon Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.